Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators
Background: Cancer patients are alleged to have poor coronavirus disease 2019 (COVID-19) outcomes. However, no systematic or comprehensive analyses of the role and mechanisms of COVID-19 receptor-related regulators in cancer are available.Methods: We comprehensively evaluated the genomic alterations...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.662460/full |
id |
doaj-fa08a9d5838648dfb298254d01b1bde4 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jian Zhang Jian Zhang Huali Jiang Kunpeng Du Tao Xie Baiyao Wang Chengcong Chen Bohong Cen Yawei Yuan Jiacai Ye |
spellingShingle |
Jian Zhang Jian Zhang Huali Jiang Kunpeng Du Tao Xie Baiyao Wang Chengcong Chen Bohong Cen Yawei Yuan Jiacai Ye Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators Frontiers in Medicine pan-cancer COVID-19 regulators genetic alterations methylation prognosis |
author_facet |
Jian Zhang Jian Zhang Huali Jiang Kunpeng Du Tao Xie Baiyao Wang Chengcong Chen Bohong Cen Yawei Yuan Jiacai Ye |
author_sort |
Jian Zhang |
title |
Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators |
title_short |
Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators |
title_full |
Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators |
title_fullStr |
Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators |
title_full_unstemmed |
Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators |
title_sort |
pan-cancer analysis of genomic and prognostic characteristics associated with coronavirus disease 2019 regulators |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Medicine |
issn |
2296-858X |
publishDate |
2021-08-01 |
description |
Background: Cancer patients are alleged to have poor coronavirus disease 2019 (COVID-19) outcomes. However, no systematic or comprehensive analyses of the role and mechanisms of COVID-19 receptor-related regulators in cancer are available.Methods: We comprehensively evaluated the genomic alterations and their clinical relevance of six COVID-19 receptor-related regulators [transmembrane serine protease 2 (TMPRSS2), angiotensinogen (AGT), angiotensin-converting enzyme 1 (ACE1), solute carrier family 6 member 19 (SLC6A19), angiotensin-converting enzyme 2 (ACE2), and angiotensin II receptor type 2 (AGTR2)] across a broad spectrum of solid tumors. RNA-seq data, single nucleotide variation data, copy number variation data, methylation data, and miRNA–mRNA interaction network data from The Cancer Genome Atlas (TCGA) of 33 solid tumors were analyzed. We assessed the sensitivities of drugs targeting COVID-19 receptor-related regulators, using information from the Cancer Therapeutics Response Portal database.Results: We found that there are widespread genetic alterations of COVID-19 regulators and that their expression levels were significantly correlated with the activity of cancer hallmark-related pathways. Moreover, COVID-19 receptor-related regulators may be used as prognostic biomarkers. By mining the genomics of drug sensitivities in cancer databases, we discovered a number of potential drugs that may target COVID-19 receptor-related regulators.Conclusion: This study revealed the genomic alterations and clinical characteristics of COVID-19 receptor-related regulators across 33 cancers, which may clarify the potential mechanism between COVID-19 receptor-related regulators and tumorigenesis and provide a novel approach for cancer treatments. |
topic |
pan-cancer COVID-19 regulators genetic alterations methylation prognosis |
url |
https://www.frontiersin.org/articles/10.3389/fmed.2021.662460/full |
work_keys_str_mv |
AT jianzhang pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators AT jianzhang pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators AT hualijiang pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators AT kunpengdu pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators AT taoxie pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators AT baiyaowang pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators AT chengcongchen pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators AT bohongcen pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators AT yaweiyuan pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators AT jiacaiye pancanceranalysisofgenomicandprognosticcharacteristicsassociatedwithcoronavirusdisease2019regulators |
_version_ |
1721211580495953920 |
spelling |
doaj-fa08a9d5838648dfb298254d01b1bde42021-08-11T07:31:38ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-08-01810.3389/fmed.2021.662460662460Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 RegulatorsJian Zhang0Jian Zhang1Huali Jiang2Kunpeng Du3Tao Xie4Baiyao Wang5Chengcong Chen6Bohong Cen7Yawei Yuan8Jiacai Ye9Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Guangzhou, ChinaGuangzhou Medical University, Guangzhou, ChinaDepartment of Cardiovascularology, Tungwah Hospital of Sun Yat-sen University, Dongguan, ChinaDepartment of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Guangzhou, ChinaDepartment of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Guangzhou, ChinaDepartment of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Guangzhou, ChinaDepartment of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Guangzhou, ChinaDepartment of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Guangzhou, ChinaDepartment of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Guangzhou, ChinaDepartment of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Guangzhou, ChinaBackground: Cancer patients are alleged to have poor coronavirus disease 2019 (COVID-19) outcomes. However, no systematic or comprehensive analyses of the role and mechanisms of COVID-19 receptor-related regulators in cancer are available.Methods: We comprehensively evaluated the genomic alterations and their clinical relevance of six COVID-19 receptor-related regulators [transmembrane serine protease 2 (TMPRSS2), angiotensinogen (AGT), angiotensin-converting enzyme 1 (ACE1), solute carrier family 6 member 19 (SLC6A19), angiotensin-converting enzyme 2 (ACE2), and angiotensin II receptor type 2 (AGTR2)] across a broad spectrum of solid tumors. RNA-seq data, single nucleotide variation data, copy number variation data, methylation data, and miRNA–mRNA interaction network data from The Cancer Genome Atlas (TCGA) of 33 solid tumors were analyzed. We assessed the sensitivities of drugs targeting COVID-19 receptor-related regulators, using information from the Cancer Therapeutics Response Portal database.Results: We found that there are widespread genetic alterations of COVID-19 regulators and that their expression levels were significantly correlated with the activity of cancer hallmark-related pathways. Moreover, COVID-19 receptor-related regulators may be used as prognostic biomarkers. By mining the genomics of drug sensitivities in cancer databases, we discovered a number of potential drugs that may target COVID-19 receptor-related regulators.Conclusion: This study revealed the genomic alterations and clinical characteristics of COVID-19 receptor-related regulators across 33 cancers, which may clarify the potential mechanism between COVID-19 receptor-related regulators and tumorigenesis and provide a novel approach for cancer treatments.https://www.frontiersin.org/articles/10.3389/fmed.2021.662460/fullpan-cancerCOVID-19 regulatorsgenetic alterationsmethylationprognosis |